Your browser doesn't support javascript.
loading
In vivo metabolism study of xiamenmycin A in mouse plasma by UPLC-QTOF-MS and LC-MS/MS.
Lei, Feng; Gao, Du; Zhang, Xi; Xu, Jun; Xu, Min-Juan.
Afiliação
  • Lei F; Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China. fiona.fenglei@sjtu.edu.cn.
  • Gao D; State Key Laboratory of Microbial Metabolism and School of Life Science & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China. huanranfanfei@163.com.
  • Zhang X; Waters Corporation, Building 13, No. 1000 Jinhai Road, Pudong New District, Shanghai 201206, China. xi_zhang@waters.com.
  • Xu J; State Key Laboratory of Microbial Metabolism and School of Life Science & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China. xujunn@sjtu.edu.cn.
  • Xu MJ; Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China. minjuanxu@sjtu.edu.cn.
Mar Drugs ; 13(2): 727-40, 2015 Jan 28.
Article em En | MEDLINE | ID: mdl-25636156
ABSTRACT
Xiamenmycin A is an antifibrotic leading compound with a benzopyran skeleton that is isolated from mangrove-derived Streptomyces xiamenensis. As a promising small molecule for fibrotic diseases, less information is known about its metabolic characteristics in vivo. In this study, the time-course of xiamenmycin A in mouse plasma was investigated by relative quantification. After two types of administration of xiamenmycin A at a single dose of 10 mg/kg, the plasma concentrations were measured quantitatively by LC-MS/MS. The dynamic changes in the xiamenmycin A concentration showed rapid absorption and quick elimination in plasma post-administration. Four metabolites (M1-M4) were identified in blood by UPLC-QTOF-MS, and xiamenmycin B (M3) is the principal metabolite in vivo, as verified by comparison of the authentic standard sample. The structures of other metabolites were identified based on the characteristics of their MS and MS/MS data. The newly identified metabolites are useful for understanding the metabolism of xiamenmycin A in vivo, aiming at the development of an anti-fibrotic drug candidate for the therapeutic treatment of excessive fibrotic diseases.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Treonina / Benzopiranos / Fibrinolíticos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Treonina / Benzopiranos / Fibrinolíticos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article